Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sagimet Biosciences Inc. - Series A Common Stock
(NQ:
SGMT
)
4.440
-0.130 (-2.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sagimet Biosciences Inc. - Series A Common Stock
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
May 07, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
May 06, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
April 22, 2024
Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
March 27, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
March 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
March 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
February 29, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
January 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
January 23, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
January 22, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
December 04, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
November 28, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
November 22, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 13, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023
October 24, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
October 18, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
September 27, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
August 21, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering
August 15, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Leadership Changes
July 20, 2023
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.